Thoughts on health economics in rheumatoid arthritis.
In this manuscript we discuss the reasons why and how health economics is important, the type of economic studies that are relevant in healthcare to different stakeholders in general, and what analyses can and have been performed in the field of rheumatoid arthritis (RA). We will thus specifically address costs and outcome measurements in RA, as well as the need for modelling in chronic progressive diseases.
Kobelt
Gisela
G
Gisela.Kobelt@he-europe.com
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D018803:Models, Economic; D017063:Outcome Assessment, Health Care / Q000191:economics; D019057:Quality-Adjusted Life Years; D040841:Resource Allocation / Q000191:economics; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D014409:Tumor Necrosis Factor-alpha